Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis

Hiroaki Nagano, Hiroshi Wada, Shogo Kobayashi, Shigeru Marubashi, Hidetoshi Eguchi, Masahiro Tanemura, Yoshito Tomimaru, Keigo Osuga, Koji Umeshita, Yuichiro Doki, Masaki Mori

Research output: Contribution to journalArticle

34 Citations (Scopus)


Background/Aim: We previously reported the beneficial effects of a combination therapy of interferon (IFN)-α/5-fluorouracil (FU) for advanced hepatocellular carcinoma (HCC) with tumor thrombi in the major portal branches. This report describes the results of longer follow-up and includes more than twice the number of patients relative to the previous report; it also evaluates the clinical predictor on the response to the combination therapy and long-term survival. Methods: The study subjects were 102 patients with advanced HCC and tumor thrombi in the major branches of the portal vein (Vp3 or 4). They were treated with at least 2 courses of IFN-α/5-FU. Results: No major treatment-related complications were noted. In the 102 patients, 40 (39.2%) showed objective response [11 (10.8%) showed complete response, 29 (28.4%) partial response], 8 (7.9%) showed no response and 54 (52.9%) showed progressive disease. Conclusion: IFN-α/5-FU combination therapy is a promising modality for advanced HCC with tumor thrombi in the major portal branches.

Original languageEnglish
Pages (from-to)63-69
Number of pages7
Issue number1-2
Publication statusPublished - Jun 1 2011
Externally publishedYes


All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this